CN Patent

CN101155600B — 放射线治疗增强剂

Assigned to Taiho Pharmaceutical Co Ltd · Expires 2011-05-04 · 15y expired

What this patent protects

本发明涉及一种放射线治疗增强剂，该放射线治疗增强剂与癌放射线疗法并用，能够降低放射线量，也能够减轻副作用。是含有(A)替加氟和(B)吉莫斯特的放射线治疗增强剂。

USPTO Abstract

本发明涉及一种放射线治疗增强剂，该放射线治疗增强剂与癌放射线疗法并用，能够降低放射线量，也能够减轻副作用。是含有(A)替加氟和(B)吉莫斯特的放射线治疗增强剂。

Drugs covered by this patent

umbralisib-tosylate (UMBRALISIB TOSYLATE)

Patent Metadata

Patent number: CN101155600B
Jurisdiction: CN
Classification: —
Expires: 2011-05-04
Drug substance claim: No
Drug product claim: No
Assignee: Taiho Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.